Express Pharma

DECEMBER 4, 2024

The post 3D printing technique could eliminate animal testing in drug development appeared first on Express Pharma.

Drug Development 105

Drug Development 105

Drug Patent Watch

NOVEMBER 24, 2024

Here, we will explore the best practices in patient centricity for generic drug development… Source This approach focuses on understanding and addressing the needs and preferences of patients to ensure that the medications they receive are safe, effective, and easy to use.

Drug Development 98

Drug Development 98

European Pharmaceutical Review

DECEMBER 23, 2024

Researchers in Australia have created an innovative drug delivery system that utilises a metalbiomolecule network (MBN) comprising of non-toxic metal ions together with phosphonate biomolecules, eg, DNA. Any additional, non-functional components in carriers can potentially increase toxicity, Dr Xu shared.

Drug Development 98

Drug Development Compounding 98

Drug Patent Watch

DECEMBER 11, 2024

These guidances are designed to streamline the development process and help ensure that generic drugs meet the same high standards of safety and efficacy as their brand-name counterparts. They offer guidance on formulation development and manufacturing considerations.

Drug Development 95

Drug Development Documentation 95

STAT

SEPTEMBER 24, 2024

Generate:Biomedicines, a Flagship Pioneering company using artificial intelligence to create new medicines, announced today that it has struck a deal with Novartis to develop an undisclosed number of targets in various disease areas. With milestone payments, the company is eligible to receive over $1 billion, in addition to royalties.

Drug Development 309

Drug Development 309

STAT

SEPTEMBER 17, 2024

Psychiatric medicine hasn’t seen much innovation in recent decades, even as many say that drugs like psilocybin, MDMA, and DMT can offer real hope to millions of people who suffer from mental illnesses like post-traumatic stress disorder, depression, anxiety, and addiction.

Drug Development 309

Drug Development 309

STAT

AUGUST 22, 2024

The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and potentially harms — the billions of people of color on the planet.

Drug Development 318

Drug Development 318

Drug Patent Watch

DECEMBER 11, 2024

This article outlines key considerations and strategies for developing a sustainable generic drug development strategy. Pfizer, for example, has been applying green chemistry principles in drug development for over two decades to reduce waste, minimize resource use, and develop energy-efficient manufacturing processes.

Drug Development 98

Drug Development 98

STAT

FEBRUARY 4, 2025

The National Cancer Institute (NCI) has had a taxpayer-funded drug development program for nearly 70 years, initiated at a time when there was no private investment in oncology drugs. 

Drug Development 294

Drug Development 294

Drug Patent Watch

FEBRUARY 12, 2025

Accelerating Generic Drug Development: Strategies for Success As a pharmaceutical professional, you know how crucial it is to navigate the complex landscape of generic drug development. The generic drug development process involves several stages, from patent research to regulatory approvals.

Drug Development 81

Drug Development Communication 81

STAT

OCTOBER 9, 2024

In the last year, pharma incumbents have leaned into partnerships with AI-driven startups to supercharge drug discovery efforts. High-powered models of protein structure and molecule binding can help identify new disease targets, and even help design new drugs.

Drug Development 335

Drug Development 335

STAT

SEPTEMBER 3, 2024

Kathy Giusti was diagnosed with multiple myeloma in 1996, when she was a 37-year-old executive at the drug company G.D. The group has raised more than $600 million for research, launched nearly 100 clinical trials, and helped bring more than 15 new drugs to market. She was told she had three years to live.

Drug Development 362

Drug Development 362

STAT

JANUARY 10, 2025

Industry-wide, AI tools are reducing drug development time by as much as  10X and bringing greater efficiencies and momentum to the most  time-consuming pharma process  of all: clinical trials. The good news: AI is starting to unlock the progress the industry needs. Continue to STAT+ to read the full story…

Drug Development 312

Drug Development 312

PharmaVoice

OCTOBER 15, 2024

A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.

Drug Development 289

Drug Development 289

STAT

SEPTEMBER 8, 2023

But in recent years, progress in the world of ALS research and drug development has come to embody a conundrum with far broader implications: The balance between moving aggressively on promising new cures and guarding against false hope. A diagnosis of ALS has long been seen as a death sentence. Read the rest…

Drug Development 363

Drug Development 363

STAT

MAY 20, 2024

But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing. Artificial intelligence is a rapidly improving technology. To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets.

Drug Development 360

Drug Development 360

STAT

APRIL 22, 2024

And how much dystrophin he has in his body depends on the ability of drug developers to continue improving it with innovation. In its absence, the house of cards comes down. For my 6-year-old son, Charlie, dystrophin will govern how long he lives. Read the rest…

Drug Development 318

Drug Development 318

STAT

OCTOBER 12, 2023

Peter Marks wants drug developers to ask more stupid questions.    It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances.

Drug Development 355

Drug Development 355

STAT

SEPTEMBER 9, 2024

To be clear, I’m not writing this to claim credit for discovery or development of GLP-1s or anything like that. Rather, I think the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. Read the rest…

Drug Development 355

Drug Development Pharmaceutical Companies Pharmaceutical Companies 355

STAT

AUGUST 19, 2024

And the startup was based in Salt Lake City, Utah — an area better known for its ski slopes and connection to the Church of Jesus Christ of Latter-day Saints than drug development.      Continue to STAT+ to read the full story…

Medical Schools 362

Medical Schools Drug Development Pharmaceutical Companies Pharmaceutical Companies 362

STAT

SEPTEMBER 5, 2024

Pediatric cancer researchers hoping to advance care have had to rely largely on repurposing newer drugs developed for adults — a limited strategy, as pediatric malignancies often have unique biology that require unique drugs.    On Thursday, though, two U.K.

Chemotherapy 322

Chemotherapy Drug Development 322

PharmaVoice

MARCH 17, 2025

Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

Drug Development 147

Drug Development 147

PharmaVoice

FEBRUARY 12, 2025

As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.

Drug Development 262

Drug Development 262

STAT

JANUARY 30, 2024

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

Drug Development 332

Drug Development 332

STAT

SEPTEMBER 5, 2024

We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year.

Drug Development 329

Drug Development 329

STAT

JULY 12, 2024

Over the past decade, precision medicine has evolved from merely creating personalized treatment plans and delivery methods to being integral throughout the entire drug development process. A similar approach needs to be implemented at scale for clinical trials. Read the rest…

Drug Development 299

Drug Development 299

STAT

SEPTEMBER 3, 2024

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug developer. 

Drug Development 347

Drug Development 347

PharmaVoice

JANUARY 10, 2025

Coming changes that could impact pharma from drug development to launch.

Drug Development 247

Drug Development 247

STAT

JANUARY 17, 2024

Recursion, a biotechnology firm that uses machine learning for drug development and and which was announcing that it is rolling out AI-driven drug discovery software with tech giant Nvidia, decided to seize the moment. It was going to rain.

Drug Development 346

Drug Development 346

STAT

OCTOBER 17, 2024

Likely more than in any other industry, patents are essential to incentivize R&D in biopharmaceuticals due to the extremely lengthy, costly, and risky nature of drug development.

Drug Development 337

Drug Development Pharmaceutical Companies Pharmaceutical Companies 337

STAT

MAY 22, 2024

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition. HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function.

Immunization 332

Immunization Immunity Drug Development 332

STAT

OCTOBER 25, 2023

The drug, called BIIB080, is being developed by Biogen. “We are very encouraged by the consistency of the data,” said Priya Singhal, Biogen’s chief of drug development, while also emphasizing the company is not trying to oversell the significance of the findings.

Drug Development 361

Drug Development 361

STAT

AUGUST 20, 2024

19 letter that the House China committee sent to the Food and Drug Administration.    The bipartisan inquiry jeopardizes yet another aspect of drug development for which drugmakers increasingly rely on China, where it’s cheaper.   “For over a decade, it appears that U.S.

Hospitals 349

Hospitals Drug Development 349

STAT

JUNE 27, 2024

STAT chief Washington correspondent Rachel Cohrs Zhang joins the podcast to talk about a new proposal for obesity drug coverage in Washington and what to expect from the first presidential debate.   Read the rest…

Drug Development 309

Drug Development 309

STAT

OCTOBER 14, 2024

Biotech investors have been buzzing around new areas of drug development this year, such as the red-hot obesity market. But there’s one field that has seen an even more significant amount of activity: autoimmune diseases.

Immunization 363

Immunization Immunity Drug Development 363

STAT

JULY 25, 2024

Many people were stunned when an FDA advisory committee voted “no” on a new drug application for MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) earlier this summer. Several things were stacked against approval: The FDA greenlights only about 50 new drugs each year. I was not among them.

Compounding 340

Compounding Drug Development 340

STAT

OCTOBER 30, 2024

Axonis will use the funds to jump into an emerging area of drug development: non-addictive therapies for pain.  Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, and others also participated in the financing round.   Continue to STAT+ to read the full story…

Drug Development 286

Drug Development 286